Xenetic Biosciences, Inc. XBIO 深 沪
等待开盘 05-14 09:30:00 美东时间
3.18
+0.155
+5.14%
华盛通- 最 高3.20
- 今 开2.95
- 成交量 1.61万股
- 最 低 2.95
- 昨 收 3.0246
- 总市值 728.56万
- 52周最高 13.93
- 市盈率 静 --
- 换手率 0.70%
- 52周最低 1.90
- 委 比 50.18%
- 总股本 229.11万
- 历史最高 1074.00
- 量 比 1.58
- 振 幅 8.27%
- 历史最低 1.90
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xenetic Biosciences reports Q1 results
Xenetic Biosciences press release (XBIO): Q1 net loss decreased approximately 49% to approximately $0.5 million, compared to approximately $0.9 million for the same period in 2025. Royalty revenue inc...
05-13 20:26
Xenetic Biosciences Q1 EPS $(0.20) Up From $(0.59) YoY, Sales $806.923K Up From $593.261K YoY
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.20) per share. This is a 66.1 percent increase over losses of $(0.59) per share from the same period last year. The company reported $806.923 thousand
05-13 05:27
Xenetic Biosciences Grants Equity Award to Interim CEO
An announcement from Xenetic Biosciences ( ($XBIO) ) is now available. On April...
04-25 06:16
Xenetic Biosciences reports FY results
Xenetic Biosciences press release (XBIO): FY Net loss for the year ended December 31, 2025 was approximately $2.7 million, reflecting investment in the Company's most promising scientific programs. R...
03-14 03:26
Xenetic Biosciences Q4 EPS $(0.22) Beats $(0.52) Estimate, Sales $766.296K Beat $690.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.52) by 57.69 percent. This is a 67.65 percent increase over losses of $(0.68) per share
03-13 20:11
Xenetic Biosciences faces ongoing delays in annual meeting
An update from Xenetic Biosciences ( ($XBIO) ) is now available. On December 11...
01-10 06:15
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
Xenetic Biosciences Executes 4-Month Extension Of Collaboration With Institute Investigator At Scripps Research To Advance Development Of R&D Program Evaluating Combination Of Systemic Dnase I And CAR T-Cell Therapies
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has
2025-11-19 21:47
Xenetic Biosciences Q3 EPS $(0.33) Beats $(0.49) Estimate, Sales $1.027M Beat $630.000K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.49) by 32.65 percent. This is a 17.86 percent decrease over losses of $(0.28) per share
2025-11-13 21:49
Xenetic Biosciences Announces Public Offering Pricing
Xenetic Biosciences ( ($XBIO) ) has provided an announcement. On October 10, 20...
2025-10-14 21:21
